Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping review
- 15 February 2022
- journal article
- review article
- Published by Elsevier in Medicina de Familia. SEMERGEN
- Vol. 48 (4) , 275-292
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Primary and Secondary Prevention of Cardiovascular DiseaseChest, 2012
- Effect of Aspirin Dose on Mortality and Cardiovascular Events in People with Diabetes: A Meta-AnalysisJournal of General Internal Medicine, 2011
- Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysisCardiovascular Diabetology, 2011
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Aspirin for the Primary Prevention of Cardiovascular EventsDiabetes Care, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusionsEuropean Heart Journal, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989
- Randomised trial of prophylactic daily aspirin in British male doctorsBMJ, 1988